Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06390774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Name: A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors — clinical trial record (NCT06390774)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Started2024-05-30

View on ClinicalTrials.gov ↗

Amendment history

2024-10-16

Study Identification, Study Status, Oversight v1

Start dateestimated 2024-04→confirmed 2024-05-30

Study titlerevised

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients ~~With~~with Advanced Malignant Tumors

2024-04-24

Original filing

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

22 trials monitored

See all monitored trials

This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.

Trial Details

NCT Number	NCT06390774
Lead Sponsor	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions	Locally Advanced, Recurrent or Metastatic Malignancies
Enrollment	180 participants
Start Date	2024-05-30
Primary Completion	2026-12 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2024-10-18